Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

An arrangement of pills of the opioid oxycodone-acetaminophen in New York. Photo / Patrick Sison / AP

A new law backed by opioid distributors and manufacturers is making it harder for the Drug Enforcement Administration to hold companies accountable for violating drug laws, according to retired DEA investigators.

The officials' accounts are the latest component of a deep-rooted investigation by the Washington Post and "60 Minutes," which initially exposed how the drug legislation was derailing the DEA's efforts to crack down on the opioid epidemic. That investigation ultimately led to the withdrawal of Rep. Tom Marino's drug czar nomination.

Why it matters: The opioid epidemic "claimed nearly 200,000 lives between 2000 and 2016," according to the Post.

Background:

  • The Ensuring Patient Access and Effective Drug Enforcement Act of 2016 was passed in Congress by a group of lawmakers supported by powerful drug companies.
  • Marino was the bill's main sponsor in the House, and Sen. Orrin Hatch (R-Utah) negotiated its final version with the DEA in the Senate.
  • Prior to the law, the DEA was able to immediately suspend drug shipments that posed an “imminent danger" to the community. Now the DEA must prove that a company’s actions represent “a substantial likelihood of an immediate threat,” according to the Post. The law also allows companies to submit “corrective action plans” before the DEA can sanction them, something one retired DEA employee called a "get out of jail free card."

What they're saying: DEA investigators say the law has undermined their agency and thwarted several of their efforts, such as stopping suspicious shipments of prescription pain pills and enforcing pharmaceuritical regulations.

The other side: Defenders of the law argue it protects patients' access to necessary prescriptions by encouraging cooperation between the DEA and drug companies. “This was an effort to ensure that DEA’s praiseworthy efforts to stem abuse don’t end up hurting legitimate patients,” Hatch said during a Senate Judiciary Committee hearing Tuesday.

What's next: The DEA investigators' full interviews with the Washington Post and "60 Minutes" will be published and broadcast on Sunday.

Go deeper

Biden confronts mounting humanitarian crisis at the border

Illustration: Eniola Odetunde/Axios. Photo: Pool/Getty Images     

Just over a month into his presidency, President Biden is staring down a mounting crisis at the border that could be just as bad as the ones faced by Barack Obama and Donald Trump, if not worse.

Why it matters: Immigration is an issue that can consume a presidency. It's intensely and poisonously partisan. It's complicated. And the lives and welfare of vulnerable children hang in the balance.

Erica Pandey, author of @Work
2 hours ago - Economy & Business

The rise of vaccine passports

Illustration: Annelise Capossela/Axios

Vaccine passports were touted early in the pandemic as an important piece of the plan to get people back to normal life. Now they’re becoming a reality.

Driving the news: CLEAR, the secure digital identity app that you see in airports around the world, and CommonPass, a health app that lets users securely access vaccination records and COVID test results, have joined forces.

"Vaccine tourism" stretches states' supplies

Illustration: Sarah Grillo/Axios

Americans who are highly motivated to get vaccinated are traveling across state lines after hearing about larger vaccine supplies or loopholes in sign-up systems.

Why it matters: "Vaccine tourism" raises ethical and legal questions, and could worsen the racial socioeconomic and racial inequalities of the pandemic.